AU2002346859C1 - Macrolides containing pharmaceutical compositions - Google Patents

Macrolides containing pharmaceutical compositions Download PDF

Info

Publication number
AU2002346859C1
AU2002346859C1 AU2002346859A AU2002346859A AU2002346859C1 AU 2002346859 C1 AU2002346859 C1 AU 2002346859C1 AU 2002346859 A AU2002346859 A AU 2002346859A AU 2002346859 A AU2002346859 A AU 2002346859A AU 2002346859 C1 AU2002346859 C1 AU 2002346859C1
Authority
AU
Australia
Prior art keywords
compound
formula
amino
propanediol
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002346859A
Other languages
English (en)
Other versions
AU2002346859A1 (en
AU2002346859B2 (en
Inventor
Josef Gottfried Meingassner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0127341A external-priority patent/GB0127341D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2002346859A1 publication Critical patent/AU2002346859A1/en
Application granted granted Critical
Publication of AU2002346859B2 publication Critical patent/AU2002346859B2/en
Publication of AU2002346859C1 publication Critical patent/AU2002346859C1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2002346859A 2001-10-23 2002-10-22 Macrolides containing pharmaceutical compositions Ceased AU2002346859C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0125443.2A GB0125443D0 (en) 2001-10-23 2001-10-23 Organic Compounds
GB0125443.2 2001-10-23
GB0127341A GB0127341D0 (en) 2001-11-14 2001-11-14 Organic compounds
GB0127341.6 2001-11-14
PCT/EP2002/011799 WO2003035068A1 (en) 2001-10-23 2002-10-22 Macrolides containing pharmaceutical compositions

Publications (3)

Publication Number Publication Date
AU2002346859A1 AU2002346859A1 (en) 2003-07-03
AU2002346859B2 AU2002346859B2 (en) 2006-03-02
AU2002346859C1 true AU2002346859C1 (en) 2008-07-10

Family

ID=26246689

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002346859A Ceased AU2002346859C1 (en) 2001-10-23 2002-10-22 Macrolides containing pharmaceutical compositions

Country Status (19)

Country Link
US (1) US7259170B2 (https=)
EP (1) EP1439838A1 (https=)
JP (1) JP2005509634A (https=)
KR (2) KR100978971B1 (https=)
CN (1) CN1307993C (https=)
AU (1) AU2002346859C1 (https=)
BR (1) BR0213463A (https=)
CA (1) CA2458690C (https=)
EC (1) ECSP045086A (https=)
GB (1) GB0125443D0 (https=)
HU (1) HUP0402108A3 (https=)
IL (1) IL160973A0 (https=)
MX (1) MXPA04003738A (https=)
NO (1) NO20042074L (https=)
NZ (1) NZ532412A (https=)
PL (1) PL368533A1 (https=)
RU (1) RU2321402C2 (https=)
WO (1) WO2003035068A1 (https=)
ZA (1) ZA200401711B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512946A (ja) * 2001-05-09 2005-05-12 ノバルティス アクチエンゲゼルシャフト 選択的免疫調節法
BR0306811A (pt) 2002-01-11 2004-10-26 Sankyo Co Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
JP2005272453A (ja) 2004-02-24 2005-10-06 Sankyo Co Ltd アミノアルコール化合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68921934T2 (de) 1988-06-29 1995-10-19 Merck & Co Inc Immunsuppressives Agens.
DK0427680T3 (da) * 1989-11-09 1995-12-18 Sandoz Ltd Heteroatom-holdige cykliske forbindelser
US5352671A (en) * 1989-11-09 1994-10-04 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
GB2252041A (en) * 1991-01-23 1992-07-29 Fujisawa Pharmaceutical Co Use of macrolide compounds in treatment of autoimmune myocarditis
CA2106483A1 (en) * 1991-03-19 1992-09-20 Vithal J. Rajadhyaksha Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers
US5247076A (en) * 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
GB9203636D0 (en) * 1992-02-19 1992-04-08 Lucas Ind Plc Fuel pumping apparatus
US5604229A (en) * 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
JPH08507789A (ja) 1993-03-17 1996-08-20 アボツト・ラボラトリーズ 大環状アミド及び尿素免疫調節剤
US5590460A (en) * 1994-07-19 1997-01-07 Tessera, Inc. Method of making multilayer circuit
DE69524962D1 (de) * 1994-08-22 2002-02-14 Welfide Corp Benzolderivate und deren medizinische verwendung
GB9521322D0 (en) 1995-10-17 1995-12-20 Sandoz Ltd Organic compounds
JPH11209277A (ja) 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
ATE298740T1 (de) * 1997-04-04 2005-07-15 Mitsubishi Pharma Corp 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
GB9713730D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
GB0003932D0 (en) 2000-02-18 2000-04-12 Novartis Ag Pharmaceutical compositions
EP1355588B1 (en) 2000-12-22 2007-08-15 Avantec Vascular Corporation Device for delivery of therepeutic agents

Also Published As

Publication number Publication date
US20040192716A1 (en) 2004-09-30
CA2458690A1 (en) 2003-05-01
CA2458690C (en) 2011-01-25
ECSP045086A (es) 2004-06-28
PL368533A1 (en) 2005-04-04
KR20090114483A (ko) 2009-11-03
KR100978971B1 (ko) 2010-08-30
JP2005509634A (ja) 2005-04-14
WO2003035068A1 (en) 2003-05-01
BR0213463A (pt) 2004-11-09
ZA200401711B (en) 2004-10-21
HUP0402108A3 (en) 2008-02-28
IL160973A0 (en) 2004-08-31
NO20042074L (no) 2004-05-19
MXPA04003738A (es) 2004-07-23
CN1307993C (zh) 2007-04-04
AU2002346859B2 (en) 2006-03-02
RU2321402C2 (ru) 2008-04-10
CN1575173A (zh) 2005-02-02
US7259170B2 (en) 2007-08-21
KR20040052250A (ko) 2004-06-22
EP1439838A1 (en) 2004-07-28
RU2004116067A (ru) 2005-04-20
NZ532412A (en) 2006-01-27
HUP0402108A2 (hu) 2005-02-28
GB0125443D0 (en) 2001-12-12

Similar Documents

Publication Publication Date Title
KR101476451B1 (ko) 자가면역성 질환의 치료
CN1146411C (zh) 1,3-丙二醇衍生物的新用途
US20080015261A1 (en) Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
US8809316B2 (en) Use of immunosuppressant compounds in a new indication
JP2007262082A (ja) 多発性硬化症の処置のためのリルゾールの使用
AU2002346859C1 (en) Macrolides containing pharmaceutical compositions
AU2002346859A1 (en) Macrolides containing pharmaceutical compositions
JP2008516961A (ja) 神経変性障害を処置することにおける使用のためのカルバメート化合物
MXPA00012248A (es) Incrementadores de acetilcolina.
AU2009284224B2 (en) Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies
JP2558147B2 (ja) 免疫性疾患治療剤
Nattero et al. Reserpine for migraine prophylaxis
HK1060855B (en) Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
HK1156229B (en) Azetidine derivative for the treatment of peripheral neuropathies

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 12 FEB 2008.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 12 FEB 2008

MK14 Patent ceased section 143(a) (annual fees not paid) or expired